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bjectives This study sought to assess safety and efﬁcacy of implantation of the Catania Coronary
tent System with Nanothin Polyzene-F (CeloNova BioSciences, Newnan, Georgia) in human coro-
ary arteries with clinical data and comprehensive intracoronary imaging.
ackground Novel approaches to modify stents (e.g., bioactive agents, coatings) have been devel-
ped to address the limitations of bare-metal and drug-eluting stents (e.g., restenosis, target lesion
evascularization [TLR], late thrombosis).
ethods This ﬁrst-in-man study using the Catania stent is a prospective, single center, nonrandom-
zed, single-arm study of 55 patients with symptomatic ischemic heart disease with de novo, ob-
tructive lesions of native coronary arteries.
esults Acute angiographic success was 100%. A core laboratory analyzed quantitative coronary an-
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emic Research Consortium–deﬁned stent thrombosis was observed at 12 months. The incidence of TLR
t 12 months was clinically driven TLR 3.6% (2 of 55) and nonclinically driven TLR 7.3% (4 of 55).
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opulation. Polyzene-F coated stents may be an alternative to both bare-metal and drug-eluting
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198are-metal stents (BMS) are associated with binary reste-
osis (BR) rates of approximately 25% at 6 to 9 months and
arget lesion revascularization (TLR) rates of 10% to 25% at
year (1). The Driver BMS (Medtronic Vascular, Santa
osa, California), for example, had an in-stent BR rate of
2.7% in the ENDEAVOR II (Randomized Comparison
f the Endeavor ABT-578 Drug-Eluting Stent with a
are-Metal Stent for Coronary Revascularization) study (2)
nd a 15.7% to 26.9% BR was reported for the Multi-Link
ision (Abbott Vascular, Abbott Park, Illinois). Drug-
luting stents (DES) significantly reduce the rates of reste-
osis and TLR when compared with BMS in patients with
ymptomatic coronary artery disease (3–5).
Although DES have been
shown to decrease restenosis
rates, they are associated with an
increased risk of 0.13% to 0.18%
per year of late stent thrombosis
compared with BMS (6). Fur-
ther, current guidelines suggest
that DES implantation should
be followed by long-term dual
antiplatelet therapy (DAPT)
with the attendant increased cost
and risk of severe bleeding (7).
Therefore, novel approaches
modifying stents in a manner or
another have been developed to
address the limitations of BMS
and DES.
Polyzene-F (CeloNova Bio-
Sciences, Newnan, Georgia) is a
unique and proprietary formula-
tion of poly[bis(trifluoroethoxy)-
phosphazene]. It is an inorganic,
high molecular weight, ultra-
pure polymer that can be used to
coat multiple substrates and can
be applied on stents as an
40-nm surface modification.
Recent animal studies have
hown that stents treated with a nanothin surface of
olyzene-F are effective in reducing in-stent restenosis,
nd when compared with uncoated stents, these coated
tents have an optimal profile in terms of thromboresis-
ance and inflammation and promote normal endothelial
ell growth (8).
The Catania stent (CeloNova BioSciences) is a flexible,
obalt chromium, balloon-expandable stent. Its Polyzene-F
urface is bacteria-resistant and anti-inflammatory, reduces
erioperative and post-procedural platelet activation and
gglomeration, and helps to prevent tissue reactions that
bbreviations
nd Acronyms
MS  bare-metal stent(s)
R  binary restenosis
APT  dual antiplatelet
herapy
ES  drug-eluting stent(s)
IM  first-in-man
VUS  intravascular
ltrasound
LL  late lumen loss
I  myocardial infarction
LD  minimal lumen
iameter
IHV  neointimal
yperplasia volume
CT  optical coherence
omography
CA  quantitative coronary
ngiography
T  stent thrombosis
LR  target lesion
evascularization
VR  target vessel
evascularizationead to restenosis (8). oThe purposes of the ATLANTA (Assessment of The
Atest Non-Thrombogenic Angioplasty stent) first-in-man
FIM) prospective study were to assess the feasibility, safety,
nd efficacy of the Catania Coronary Stent System implan-
ation in human coronary arteries using clinical evaluation,
uantitative coronary angiography (QCA), intravascular
ltrasound (IVUS), and optical coherence tomography
OCT) follow-up.
ethods
tudy design. The study was designed as a prospective,
ingle center, nonrandomized, single-arm study. A total of
5 patients with stable or unstable angina and/or documen-
ation of myocardial ischemia attributable to native coronary
rtery stenosis, and amenable to treatment by percutaneous
tenting, were enrolled in the ATLANTA trial from May
007 through August 2007. Enrollment criteria included
atients older than 30 years and younger than 70 years with
p to 2 de novo type A and/or B American Heart Associ-
tion/American College of Cardiology lesions to be treated
ith the Catania stent in a vessel with a reference diameter
2.5 and 3.5 mm by visual assessment. Major clinical/
nstrumental and angiographic/procedural exclusion criteria
re summarized in Table 1. The study was conducted
ccording to the Declaration of Helsinki. The local medical
thics committee approved the protocol and written in-
ormed consent was obtained from every patient.
ata collection and core laboratory analyses. All clinically
elevant baseline variables were recorded on electronic case
eport forms. The clinical in-hospital and follow-up data
elated to medications and clinical status were prospectively
ollected through scheduled outpatient clinic evaluations.
xercise stress test was scheduled at 5 weeks and 6 months.
eferring cardiologists, general practitioners, and patients
ere contacted whenever necessary for further information.
ll repeat coronary intervention and rehospitalization data
ere prospectively collected during follow-up and entered
nto the centralized computer system of our institution or by
irectly contacting the hospitals where the patients were
dmitted or referred. Clinical events were adjudicated by an
ndependent clinical events committee.
All QCA, IVUS, and OCT analyses were performed
ffline by an independent, validated core laboratory (Rome
eart Research, Rome, Italy) (9,10).
UANTITATIVE CORONARY ANALYSIS. The QCA images
nd analyses were obtained following a validated method-
logy. All angiograms were analyzed using a computer-
ssisted automated edge-detection algorithm (CMS, Medis,
edical Imaging Systems, BV, Leiden, the Netherlands)
sing standard qualitative definitions and quantitative cor-
nary angiographic measurements obtained in 2 orthogonal
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199iews. The following measured parameters were minimal
umen diameter (MLD), reference vessel diameter, percent
iameter stenosis, in-stent late lumen loss (LLL), and BR.
VUS. The IVUS examinations were performed in all pa-
ients at the completion of the stenting procedure and at
-month follow-up. The IVUS images were obtained with
echanical ultrasound imaging catheters at 40 MHz (At-
antis 2.9-F, Boston Scientific Corp., Natick, Massachu-
etts). Images were obtained after intracoronary administra-
ion of 200 g of nitroglycerin to prevent possible
asospasm. The imaging probe was positioned distally to
he target lesions and withdrawn at a constant speed of 0.5
m/s using a motorized pullback device. Offline analyses
ere done with the EchoPlaque software (INDEC Medical
ystems, Santa Clara, California). Lumen, stent, and exter-
al elastic membrane contours were analyzed at a distance of
.5 mm in the stented segment. The following measure-
ents were obtained: mean stent volume, lumen volume,
eointimal hyperplasia volume (NIHV), and percentage of
IHV.
CT. Fifteen patients were randomly assigned to OCT
xamination at the completion of the stenting procedure
Table 1. Exclusion Criteria
Clinical
Age 30 or 70 yrs
Life expectancy 1 yr
Chronic renal failure (serum creatinine 2 mg/dl)
Ongoing acute myocardial infarction or myocardial infarction within the last 48 h
Left ventricular ejection fraction 30%
Cardiogenic shock
Documented or suspected systemic and/or infectious disease
Hypersensitivity to cobalt chromium or contrast media
Antithrombotic drug intolerance
Cardiac and/or extracardiac documented disease requiring surgical repair
Patient is not acceptable candidate for emergent coronary artery bypass graft
Primary or secondary pulmonary hypertension (by echo-Doppler)
In-stent restenosis
Recent (6 months) percutaneous coronary intervention or coronary artery
bypass graft
Angiographic
Vessel size 2.5 or 3.5 mm
Lesion length 20 mm
Planned 2 stents implantation (except bail-out)
Other type of stent implantation
Visible endocoronary thrombosis
Diffuse, severe coronary calciﬁcations
Use of debulking devices
Extreme vessel tortuosity
Unprotected left main stenosis
Bifurcation lesion
Saphenous vein graft and arterial bypass (internal mammary artery)
Chronic total occlusionnd at 6-month follow-up. tThe M2 LightLab OCT wire (ImageWire, Light Imag-
ng Inc., Westford, Massachusetts) was used. ImageWire
as an outer diameter of 0.019 inches and contains a
.006-inch fiberoptic imaging core (0.4 mm in diameter)
nd a distal radiopaque spring tip, similar to conventional
uidewires.
The OCT images were obtained with a recently devel-
ped nonocclusive technique (11,12). Briefly, OCT image
cquisition was performed after coronary cannulation with a
-F guiding catheter and intravenous administration of 50
/kg of heparin. The OCT image wire was then positioned
n the target vessel and pulled back at 2-mm/s speed; OCT
rames were acquired at a frame rate of 15.6/s. The infusion
rotocol requires a manual injection of iodixanol 320
Visipaque, GE Health Care, Cork, Ireland) from the
uiding catheter at an infusion rate between 2 and 4 cc/s,
ased on the run-off of the artery and the online assessment
f OCT image quality. Consistent with IVUS assessment,
CT cross-sections were analyzed at 0.5-mm intervals.
sing a published methodology (13–15), stent strut cover-
ge and malapposition was evaluated.
evice description. The Catania stent is made of a cobalt
hromium alloy and is surface treated with Polyzene-F, a
roprietary, biocompatible, biostable formulation of poly-
bis(trifluoroethoxy) phosphazene]. The surface treatment
easures approximately 40 nm thick. In its highly purified
orm, Polyzene-F effectively reduces glycoprotein IIb/IIIa
eceptor density on thrombocytes, diminishes activation of
he clotting and complement systems, reduces adhesion,
inimizes activation and accumulation of platelets, de-
reases the infiltration of inflammatory cells, and reduces
oreign body reactions (16,17). Polyzene-F is a drug-free
urface treatment that promotes healthy endothelial cellular
rowth. The decline in the amount of thrombocyte depo-
ition on the arterial wall is associated with diminished
eointimal formation in humans (18). The stent strut
rchitecture is designed to promote polymer integration and
educe strain concentration in the critical strut area. The
atania stent has a modified open cell design with struts of
5-m thickness in the 2.0- to 2.75-mm diameters and 74
m in the 3.0- to 4.0-mm diameters, a very flexible design
nd a low crossing profile (from 1.0 mm for the 2.5-mm
tent to 1.05 mm for the 4.0-mm stent). By comparison,
ES have strut thicknesses of 81 to 140 m and polymer
hicknesses of 5.3 to 16 m (more than 1,000 times the
hickness of the Polyzene-F surface treatment). The stent is
ounted on a 0.014-inch guidewire-compatible rapid ex-
hange stent delivery system.
mplantation procedure. Interventional procedures were
erformed and adjuvant therapies were given according to
ccepted guidelines (19). All patients were pre-treated with
spirin (75 to 300 mg daily) and clopidogrel (600-mg
oading dose 6 h before or during the procedure). During
he procedure, all patients received intravenous unfraction-
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200ted heparin (50 to 150 IU/kg) to maintain activated
lotting time200 s. An intracoronary dose of nitroglycerin
00 g was administered before the first and the last
eference angiogram. Pre-dilation or direct stenting was
erformed at the discretion of the operator. Angiographic
ptimization was performed by high-pressure dilation to
chieve30% residual stenosis by visual estimate after stent
mplantation. All patients were advised to maintain lifelong
spirin therapy. Thienopyridine therapy (clopidogrel 75
g/day or ticlopidine 250 mg twice daily) was discontinued
weeks after the procedure.
nd point and deﬁnitions. Primary end points included
ardiac death, index vessel-related nonfatal myocardial in-
arction (MI), TLR, target vessel revascularization (TVR),
on-TLR, and stent thrombosis (ST). Secondary end points
ncluded procedural success, overall mortality, BR, LLL,
nd percent NIHV.
LINICAL END POINTS. A non–Q-wave MI was defined as
reatine kinase-myocardial band enzyme elevation3 times
he upper limit of the normal value; a Q-wave MI was
efined as occurrence of new pathological Q waves in the
lectrocardiogram in addition to enzyme elevation. Target
esion revascularization was defined as any clinically driven
epeat percutaneous revascularization or surgical bypass of
he original target lesion site. We defined clinically driven
evascularizations as those in which the patient had a
ositive functional study, ischemic electrocardiogram
hange at rest in a distribution consistent with the target
essel, or ischemic symptoms, and an in-lesion diameter
tenosis50% by QCA. Revascularization of a target lesion
ith an in-lesion diameter stenosis 70% (by QCA) in the
bsence of the previously mentioned ischemic signs or
ymptoms is also considered clinically driven. Nonclinically
riven TLRs were those in which the patient undergoes a
onemergent revascularization for a diameter stenosis
50% and 70% (by QCA).
We defined TVR as a reintervention driven by any lesion
ocated in the same coronary artery and included coronary
rtery bypass graft involving the infarct-related artery. Stent
hrombosis was defined as an acute coronary syndrome with
ngiographic documentation of either vessel occlusion or
hrombus within or adjacent to a previously successfully
tented vessel. According to the Academic Research Con-
ortium classification (20), ST was defined as definite
symptoms suggestive of an acute coronary syndrome and
ngiographic or pathologic confirmation of ST), probable
unexplained death within 30 days after the procedure or
arget vessel–related MI without angiographic confirmation
f ST), and possible (any unexplained death after 30 days).
Stent thromboses were also categorized according to the
iming of the event into intraprocedural, subacute throm-
osis (from the end of the procedure to 30 days), and late
tent thrombosis (30 days). gNGIOGRAPHIC END POINTS. Lesion length was measured
s the length of contiguous coronary narrowing (defined as
ercent diameter stenosis20%) containing both the target
emodynamically obstructive and adjacent nonobstructive
laque. Minimal lumen diameter was defined as the mean
LD derived from 2 orthogonal views by QCA angiogra-
hy. Percent diameter stenosis was defined as: (1  (MLD/
eference vessel diameter) 100). Acute gain was defined as
he change in MLD from pre- to post-intervention, LLL
as defined as the change in MLD between post-
ntervention and 6-month follow-up. Binary restenosis was
efined as a diameter stenosis of 50% within the stent.
ngiographic success was defined as the achievement of
30% residual stenosis by visual estimate after stent im-
lantation. Procedural success was defined as an angio-
raphically successful procedure without death, MI, or
epeat revascularization until hospital discharge.
VUS END POINTS. Mean stent area and lumen area were
alculated from manually traced contours using serial cross-
ections with an axial distance of 0.5 mm throughout the
tented segment. Stent volume and lumen volume were
alculated using Simpson’s rule. Neointimal hyperplasia
olume was computed as stent volume minus lumen volume.
ercentage NIHV was also measured as (NIHV  100/
tent volume).
CT END POINTS. Neointimal hyperplasia thickness of 0
m was defined as covered (13–15). A maximum distance
f 75 m (polymer and stent strut thickness) plus OCT
esolution (21,22) between the inner strut surface and
djacent vessel surface was defined as malapposition. Intra-
oronary thrombus was defined as a protruding mass beyond
he stent strut into the lumen.
tatistical analysis. The trial was designed to minimize the
umber of patients exposed to this investigative device while
till providing enough information for evidence of safety and
fficacy.
Baseline characteristics of patients were summarized in
erms of frequencies and percentages for categorical vari-
bles and by means with standard deviations for continuous
ariables. Continuous variables were compared using Stu-
ent’s unpaired t test. All data were processed using the
tatistical Package for Social Sciences, version 15 (SPSS
nc., Chicago, Illinois).
esults
total of 55 patients were recruited to the ATLANTA
rial, and a total of 76 lesions were treated with 89
mplanted stents. To date, baseline demographic and lesion
haracteristics of all patients have been analyzed as well as
-, 6-, and 12-month clinical outcomes for all 55 patients
100% follow-up). At 6 months, 1 asymptomatic patient
ith no evidence of myocardial ischemia refused angio-
raphic follow-up (98% follow-up), 52 patients had techni-
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201ally successful IVUS (95% follow-up), and all pre-assigned
atients had technically successful OCT.
The mean patient age was 58.6  8.6 years. Thirty-four
ercent of patients had diabetes mellitus, 63% had unstable
ngina, and 11% had evidence of recent MI (Table 2). Of
he 76 lesions treated, 89.5% were classified as American
eart Association/American College of Cardiology (10)
ype B lesions by visual estimate before the procedure. After
CA analysis, the core laboratory reclassified 15 lesions as
ype C lesions because of a longer length than visually
stimated (Table 3). The left anterior descending artery was
he target vessel in 51.3% of cases. A high number (64%) of
mall vessels 2.75 mm were enrolled with an overall
eference vessel diameter of 2.75 mm. The combination of
hese factors makes the patient population for a FIM study
nusually complex. Forty-three procedures (48%) were ac-
omplished with direct stenting and 46 (52%) with pre-
ilation.
Initial angiographic and procedural success was achieved
n 100% of patients.
LINICAL OUTCOME. The in-hospital incidence of death,
I, TVR, and/or stent thrombosis was 0%. Table 4
ummarizes the adverse event rates at 30 days, 6 months,
Table 2. Patient Characteristics (N  55)
Age, mean  SD, yrs 58.6  8.6
Male, n (%) 41 (75)
Diabetes mellitus, n (%) 19 (34)
Insulin-dependent diabetes mellitus, n (%) 6 (11)
Hypertension, n (%) 33 (60)
Hypercholesterolemia, n (%) 30 (55)
Current smoker, n (%) 23 (42)
Stable angina, n (%) 13 (24)
Unstable angina, n (%) 35 (63)
Silent ischemia, n (%) 1 (2)
Recent MI (48 h, 4 weeks), n (%) 6 (11)
Previous MI, n (%) 38 (69)
Baseline LVEF, mean  SD, % 52.2  6.7
LVEF left ventricular ejection fraction; MImyocardial infarction.
Table 3. Angiographic and Procedural Characteristics (Lesion-Based)
(N  76)
Vessels treated, n (%)
Left anterior descending artery 39 (51.3)
Left circumﬂex artery 17 (22.4)
Right coronary artery 20 (26.3)
Lesions characteristics, n (%)
Type A 8 (10.6)
Type B 53 (69.7)
Type C 15 (19.7)
Procedural characteristics, mean  SD
Lesion length, mm 13.0 4.3
Stents per lesion, n 1.2 0.4Stented segment length 19.2 7.6nd 12 months. No events were observed during the first 30
ays, but at 6 months, 1 asymptomatic patient (1.8%) had
linically driven TLR, 4 patients (7.3%) had nonclinically
riven TLR, and 2 patients (3.6%) experienced TVR
on-TLR. One additional clinically driven TLR (1.8%)
ccurred at 9 months.
UANTITATIVE CORONARY ANALYSIS. Table 5 summarizes
CA results at baseline, immediately after the procedure
nd at 6 months. Binary angiographic restenosis was ob-
erved in 5 of 74 lesions (6.8%) and in-stent LLL was 0.60
0.48 mm.
VUS ANALYSIS. The IVUS analysis data are listed in Table
. Overall percent NIHV was 27.9%. Notably, no differ-
nces were observed between diabetics and nondiabetics
ased upon all IVUS measurements.
Table 4. Early, Mid-, and Long-Term Outcomes (N  55)
30-Day
Follow-Up
6-Month
Follow-Up
12-Month
Follow-Up
Death 0 (0) 0 (0) 0 (0)
Cardiac death 0 (0) 0 (0) 0 (0)
Index vessel–related MI 0 (0) 0 (0) 0 (0)
Q-wave MI 0 (0) 0 (0) 0 (0)
Non–Q-wave MI 0 (0) 0 (0) 0 (0)
TLR clinically driven 0 (0) 1 (1.8) 2 (3.6)
CABG 0 (0) 0 (0) 0 (0)
PCI 0 (0) 1 (20) 2 (33)
TLR nonclinically driven 0 (0) 4 (7.3) 4 (7.3)
CABG 0 (0) 0 (0) 0 (0)
PCI 0 (0) 4 (80) 4 (67)
TVR non-TLR 0 (0) 2 (3.6) 2 (3.6)
Stent thrombosis 0 (0) 0 (0) 0 (0)
CABG  coronary artery bypass graft; PCI  percutaneous coronary intervention; TLR  target
lesion revascularization; TVR target vessel revascularization; other abbreviations as in Table 2.
Table 5. Quantitative Coronary Angiography
In-Stent
Reference vessel diameter, mm, mean  SD
Baseline 2.75 0.52
After procedure 2.87 0.48
At 6 months 2.55 0.50
Minimal lumen diameter, mm, mean  SD
Baseline 1.00 0.41
After procedure 2.50 0.40
At 6 months 1.91 0.64
Stenosis, % of lumen diameter, mean  SD
Baseline 64.5 11.7
After procedure 12.2 6.6
At 6 months 26.0 16.6
Acute gain, mm, mean  SD 1.51 0.49
Late lumen loss, mm, mean  SD 0.60 0.48Binary restenosis, n (%) 5 (6.8)
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202CT ANALYSIS. A total of 1,904 cross-sections were ana-
yzed (19,028 struts) by OCT. Of these, 18,933 struts
99.5%) showed evidence of coverage. The vast majority of
atients (5 of 6) with incomplete coverage exhibited a
ercentage of strut coverage greater than 99%. Malapposi-
ion was found only in 29 struts (0.15%) and was present in
patients, in which 4 stents with a total of 4,020 struts were
nalyzed. A single patient accounted for 81% and 59% of all
oncovered and malapposed struts, respectively.
iscussion
ES have been shown to reduce the risks of both restenosis
nd TLR after elective percutaneous coronary intervention,
s compared with BMS (3–5). However, DES may be
ssociated with lack of or delayed endothelialization, stent
alapposition, inflammatory or hypersensitivity reactions,
nd an increased risk of late stent thrombosis and very late
tent thrombosis (23), and usually require long-term DAPT
ith consequent bleeding risk and increased cost. The
HARISMA (Clopidogrel for High Atherothrombotic
isk, Ischemic Stabilization, Management, and Avoidance)
tudy group suggested that long-term DAPT with aspirin
nd clopidogrel is associated with a 2.1% risk of moderate
leeding requiring transfusion (24). In addition, the cost of
APT to patient or health care system is estimated to be
1,540 (€982) per year (6). Moreover, biocompatible poly-
er coatings used as drug-elution matrices may induce
ypersensitivity and/or inflammatory reactions. Thus, a
trong effort is still devoted to develop new stents with ideal
eatures such as decreased restenosis rates with decreased
hrombogenicity and without the need for long-term
APT.
Therefore, to provide a biologically inert barrier between
he stent surface, circulating blood, and endothelial wall, a
ariety of different stent coatings have been evaluated in
ultiple study registries, nonrandomized and randomized
rials (25).
The present FIM feasibility single center study assessed
he safety and efficacy of the new Catania stent in the
reatment of de novo coronary lesions. Angiographic success
Table 6. Intravascular Ultrasound Measurements at Follow-Up
All Patients
(N  55)
Stent volume, mm3, mean  SD 127.0 59.1
Luminal volume, mm3, mean  SD 89.3 40.2
NIHV, mm3, mean  SD 37.7 37.6
Percent NIHV, mean  SD 27.9 16.1
NIHV neointimal hyperplasia volume.nd procedural success were 100%. Comprehensive clinical follow-up was achieved in all patients at 30 days, with no
bserved cardiac events.
At 12-month clinical follow-up, the total TLR per
atient rate was 10.9% (7.3% nonclinically driven and
.6% clinically driven) and there was no occurrence of
eath, MI, stroke, ST, or need for surgical revasculariza-
ion. This compares very favorably with 12-month BMS
LR rates of 14.7% in the TAXUS IV (Treatment of de
ovo Coronary Disease Using a Single Paclitaxel-
luting Stent) study and 20% in the SIRIUS (Sirolimus-
luting Stent in Coronary Lesions) study and reasonably
ell against DES TLR rates of 4.2% in TAXUS IV, 4.9%
n SIRIUS (26 –28). The 0% death rate compares very
avorably with BMS (0.7% to 1.5%) to paclitaxel-eluting
tents (1.5%) and to sirolimus-eluting stents (1.1%) at 12
onths. The 0% MI rate also compares very favorably
o BMS (1.8% to 2.2%), to paclitaxel-eluting stents
0.8%) and to sirolimus-eluting stents (1.3%) at 12
onths (27).
Moreover, the 6-month BR rate of 6.8% in the present
tudy was far lower than the rate reported for stents with
onpolymeric coatings (29 –32). Another pilot study
ssessing the short- and mid-term performance of a
olyphosphazene-coated coronary stent reported a 15.6%
ate of restenosis at 6-month angiographic follow-up (33)
ut with a different stent platform of 120-m strut thick-
ess. The LLL of 0.60 mm was lower than those of BMS
34–36) and was in the range of some currently available
ES (37). Overall, with the baseline reference vessel diam-
ter of 2.75 0.52, the restenosis pattern is considered focal
nd mild. Of the 5 of 55 (9.1%) patients undergoing TLR
t 6 months, all were asymptomatic with 1 procedure
eeting the criteria for clinically driven with a BR rate
70%. The remaining 4 patients had QCA BR 50% and
70%.
Intravascular ultrasound at follow-up showed a mild
ercentage of neointimal proliferation that compares well
ith other IVUS studies on BMS (38). Interestingly, we
bserved that diabetes seems not to influence volumetric
VUS assessment of neointima in patients treated with the
atania stent. This is a very intriguing finding that needs
Patients With
Diabetes
(n  19)
Patients Without
Diabetes
(n  36) p Value
123.2 43.1 128.6 65.3 0.735
89.7 40.4 89.1 40.6 0.955
33.5 22.7 39.5 42.7 0.610
28.1 15.9 27.7 16.6 0.932urther confirmation.
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203Data from OCT analysis showed extremely low rates of
alapposition suggesting an optimal healing process. Com-
lete vessel healing visualized by OCT with evidence of
tent strut coverage in 99.5% of struts is a remarkable
nding and justifies the absence of ST reported in the study.
he investigators believe this to be the first FIM study to
nclude an OCT arm and the only study to date with a
trut-by-strut analysis of vessel healing.
Finally, the safety profile appeared excellent, as there was
o incidence of stent thrombosis from the index procedure
o 180 days of clinical and angiographic follow-up, despite
he fact that 1 patient discontinued aspirin 1 week after
mplantation and another patient discontinued both aspirin
nd ticlopidine 2 weeks after implantation. The absence of
tent thrombosis confirms the strong preclinical evidence
hat a Polyzene-F surface treatment is associated with
educed thrombogenicity and inflammatory reactions in
nimal models (8,39). This is of clinical relevance because,
n contrast to restenosis, which is not usually associated with
ncreased mortality, ST is a potentially catastrophic event
hat might manifest as MI and sudden death (22). It is
mportant to also note that at 12-month clinical follow-up
n all 55 patients, there were no deaths, stroke, or MIs
eported. These preliminary results should be confirmed
sing a larger cohort of patients, but are undoubtedly very
romising. The Catania stent, due to its safety profile may
lso represent a reliable alternative for patients who are not
ligible for long-term thienopyridine regimen.
In summary, this FIM experience showed a favorable
arly and mid-term safety profile and a high-level efficacy of
he new Catania stent in the treatment of de novo coronary
esions in a real-world patient population. The use of
olyzene-F coated stents may be an alternative to both
MS and DES, with reduced LLL, restenosis, and TLR
ithout increased risk of late and very late ST and no
equirement for long-term DAPT.
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